Synthesis and characterization of [125I]N-(2-aminoethyl)-4-iodobenzamide as a selective monoamine oxidase B inhibitor.
H Rafii, S Chalon, J E Ombetta, Y Frangin, L Garreau, A M Dognon, I Lena, S Bodard, M P Vilar, J C Besnard
Index: Nucl. Med. Biol. 22(5) , 617-23, (1995)
Full Text: HTML
Abstract
We described the radiosynthesis of an analog of Ro 16-6491, [125I]N-(2-aminoethyl)-4-iodobenzamide, for SPECT exploration of the monoamine oxidase B (MAO-B) in human brain. The radiolabelling was carried out by nucleophilic exchange of the brominated precursor at solid-state phase in presence of ammonium sulphate. The radiochemical purity of radioiodinated product was higher than 95%. In comparison with Ro 16-6491, the in vitro studies showed a good selectivity of stable N-(2-aminoethyl)-4-iodobenzamide for MAO-B but a slightly lower affinity. Biodistribution studies in the rat showed a high and selective uptake of this compound in the pineal gland 1 h after i.v. injection. The cerebral uptake was low, but the coupling of [125I]N-(2-aminoethyl)-4-iodobenzamide with a lipophilic radical to enhance the passage through the blood-brain barrier can be envisaged.
Related Compounds
Related Articles:
1995-02-01
[Br. J. Pharmacol. 114(4) , 837-45, (1995)]
Overview of the present state of MAO inhibitors.
1987-01-01
[J. Neural Transm. Suppl. 23 , 103-19, (1987)]
2005-04-01
[Synapse 56(1) , 54-6, (2005)]
1988-12-01
[Pharmacol. Res. Commun. 20 , 51, (1988)]
1988-04-01
[J. Neurochem. 50 , 1037, (1988)]